Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivamelagon in Hypothalamic Obesity (Extension)
NCT07156578Phase 2Enrolling by invitation
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LB54640 in hypothalamic obesity (HO), sponsored by Rhythm Pharmaceuticals. Started Nov 2025; status: enrolling by invitation.
02
Drugs
LB54640
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT07156578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156578.